Clinical Trials Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLCAugust 8, 2026
Clinical Trials Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialAugust 7, 2026